Mandate

Vinge advises Cinclus Pharma in connection with listing on Nasdaq Stockholm

Vinge advises Cinclus Pharma Holding AB (publ) (“Cinclus Pharma”) in connection with an offering of new ordinary shares and listing on Nasdaq Stockholm. The first day of trading is 20 June 2024.

The offering will provide Cinclus Pharma with proceeds of approximately SEK 787 million before deduction of issue costs and provided that the over-allotment option is fully exercised. In connection with the offering, Cinclus Pharma also carries out a set-off issue at the offering price to convert outstanding bridge loans. 

Cinclus Pharma is a clinical-stage pharmaceutical company focused on the development of the drug candidate linaprazan glurate, a proprietary “prodrug” of the molecule linaprazan. Linaprazan glurate represents a new and innovative mode of action for the treatment of erosive GERD.

Vinge's team mainly consists of Dain Hård Nevonen,Amanda Knutsson, Anna Svensson,Michaela Ådén and Filip Magnusson (Capital Markets and Public M&A), Stojan Arnestål (IP/Life science), Maria Schultzberg (Corporate taxation), Mathilda Persson (Commercial agreements), Gulestan Ali (Compliance), Nicklas Thorgerzon (IT/GDPR), Jonatan Stentorp (Employment) and Sofia Haggren (Financing).

Related

Vinge advises FAM AB on the acquisition of Aktiebolaget Näckström

Vinge has advised FAM AB on its acquisition of Aktiebolaget Näckström from Vectura Fastigheter AB. The principal assets of Aktiebolaget Näckström comprise the property Stockholm Näckström 6 (Arsenalsgatan 8) and Villa Täcka udden.
October 16, 2025

Vinge has advised FAM in connection with its investment in GreenIron

Vinge has advised FAM AB, owned by the Wallenberg Foundations, in connection with its investment in GreenIron H2 AB. Through the round, GreenIron raised in total SEK 125 million in additional funding from existing shareholders, with FAM now becoming the company’s largest owner.
October 16, 2025

Vinge has advised on the sale of Westcomp AB to Tången Industrikapital AB

Pursuant to the transaction, Tången acquires approximately 91 per cent of the shares in Westcomp.
October 15, 2025